共 43 条
- [1] Zeidan R.S., Han S.M., Leeuwenburgh C., Xiao R., Iron Homeostasis and Organismal Aging, Ageing Research Reviews, 72, (2021)
- [2] De Franceschi L., Iolascon A., Taher A., Cappellini M.D., Clinical Management of Iron Deficiency Anemia in Adults: Systemic Review on Advances in Diagnosis and Treatment, European Journal of Internal Medicine, 42, pp. 16-23, (2017)
- [3] Ganz T., New Regulators of Systemic Iron Homeostasis, Signal Transduction and Targeted Therapy, 6, 1, (2021)
- [4] Long H., Zhu W., Wei L., Zhao J., Iron Homeostasis Imbalance and Ferroptosis in Brain Diseases, MedComm, 4, 4, (2020)
- [5] Anderson E.R., Shah Y.M., Iron Homeostasis in the Liver, Comprehensive Physiology, 3, 1, pp. 315-330, (2013)
- [6] Basak T., Kanwar R.K., Iron Imbalance in Cancer: Intersection of Deficiency and Overload, Cancer Medicine, 11, 20, pp. 3837-3853, (2022)
- [7] Rayego-Mateos S., Rodrigues-Diez R.R., Fernandez-Fernandez B., Et al., Targeting Inflammation to Treat Diabetic Kidney Disease: The Road to 2030, Kidney International, 103, 2, pp. 282-296, (2023)
- [8] Wang Y.H., Chang D.Y., Zhao M.H., Chen M., Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1alpha/Heme Oxygenase 1-Mediated Ferroptosis, Antioxidants & Redox Signaling, 40, 7-9, pp. 492-509, (2024)
- [9] Lu Q., Yang L., Xiao J.J., Et al., Empagliflozin Attenuates the Renal Tubular Ferroptosis in Diabetic Kidney Disease Through AMPK/NRF2 Pathway, Free Radical Biology & Medicine, 195, pp. 89-102, (2023)
- [10] Huang B., Wen W., Ye S., Dapagliflozin Ameliorates Renal Tubular Ferroptosis in Diabetes via SLC40A1 Stabilization, Oxidative Medicine and Cellular Longevity, 2022, (2022)